Medtronic plc (NYSE: MDT), a healthcare technology company, on Tuesday said the US Food and Drug Administration (FDA) has cleared its Hugo robotic-assisted surgery (RAS) system for general surgery procedures.
The clearance covers all upper abdominal general surgical procedures, including cholecystectomy, Roux-en-Y gastric bypass, ventral hernia and small bowel resection. Inguinal hernia and appendectomy, both lower abdominal procedures, were also cleared. Together, these account for about 3.5 million US surgeries a year, more than half of all soft-tissue procedures performed in the country annually.
Medtronic said that, globally, Hugo RAS system procedure growth is running at more than twice the pace of the robotic surgery market. The company expects to surpass 50,000 procedures by the end of its fiscal year. Outside the US, general surgery has become the highest-growth area for the system, ahead of urology and gynaecology.
For US hospitals, the decision widens the system's use beyond urology.
Harbour BioMed's partner Spruce Biosciences separates CRHX-101 into Adrenyx Biosciences
US FDA clears Medtronic plc's Hugo robotic-assisted surgery system for general surgery
Sobi's Tryngolza for severe hypertriglyceridaemia receives EU approval
Apotex launches generic version of INLYTA in US market
Genentech secures first FDA approval for primary membranous nephropathy treatment
ViiV Healthcare receives positive EU recommendation for expanded paediatric HIV treatments
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Sunnyside adds GLP-1 options to its medication program for Alcohol Use Disorder